key: cord-0686182-3fcp2198 authors: Padilla‐Rojas, Carlos; Jimenez‐Vasquez, Victor; Hurtado, Veronica; Mestanza, Orson; Molina, Iris S.; Barcena, Luis; Morales Ruiz, Sandra; Acedo, Steve; Lizarraga, Wendy; Bailon, Henri; Cáceres, Omar; Galarza, Marco; Rojas‐Serrano, Nancy; Vargas‐Herrera, Natalia; Lope‐Pari, Priscila; Huayra, Joseph; Solari, Lely title: Genomic analysis reveals a rapid spread and predominance of lambda (C.37) SARS‐COV‐2 lineage in Peru despite circulation of variants of concern date: 2021-08-20 journal: J Med Virol DOI: 10.1002/jmv.27261 sha: 271c514264982aadf667523a1f995c59635704fe doc_id: 686182 cord_uid: 3fcp2198 The pandemic generated by SARS‐Cov‐2 has caused a large number of cases and deaths in the world, but South America has been one of the continents that were most hard hit. The appearance of new variants causes concern because of the possibility that they may evade the protection generated by vaccination campaigns, their greater capacity to be transmitted, or their higher virulence. We analyzed the circulating variants in Peru after improving our Genomic Surveillance program. The results indicate a steep increase of the lambda lineage (C.37) until becoming predominant between January and April 2021, despite the cocirculation of other variants of concern or interest. Lambda lineage deserves close monitoring and could probably become a variant of concern in the near future. The SARS-CoV-2 has generated epidemics of different social and sanitary impacts and characteristics throughout the world. From December 2020, the emergence of viral variants of SARS-CoV-2 has been associated with higher transmissibility, immune escape, or increased pathogenicity. The variants of concern (VOC) and variants of interest (VOI), having different epidemiological and clinical characteristics, represent an important threat to the global containment of the pandemic. 1, 2 Peru has been one of the countries hardest hit by the pandemic. From January to June, a devastating second wave caused more than 980 485 reported cases and 98 837 deaths. 3 However, due to its limited capacities of genomic sequencing, tracing the circulating variants was very hard. The alpha (B.1.1.7) variant was first reported in our country in December 2020, 4 whereas in January 2021, the gamma (P.1) variant was identified in three regions of our country, most of all in the Amazonian regions. 5 In April 2021, the lambda (C.37) lineage was reported in patients from the capital city of Lima. 6 The first patient having this lineage can be traced in the Global Initiative on Sharing Avian Influenza Data (GISAID) back to November 2020 (Lima). Currently, this lineage has also been identified in the United States, Chile, Brazil, Argentina, Ecuador, Mexico, Spain, and Germany, among other countries. 5 Since May, Peru has scaled up its capacity of genomic surveillance through the implementation of a genomic platform using the Illumina COVIDSEQ test. The aim of this report is to describe the main SARS-CoV-2 lineages circulating in our country during the second wave, from January to April 2021, and to model their In addition, relevant genomes were mined from the GISAID database 5 : 1246 genomes registered from Peru and other relevant genomes reported in the database were selected randomly. All samples were processed using Illumina's COVIDSeq platform according to a previously described protocol. 7 Figure 1A and Table S1 ). In April 2021, the gamma variant showed high prevalence in the The phylogenetic analysis shows that the studied genomes are grouped into clusters with good support and an association that was previously reported for Peru and other countries ( Figure 1C ). The main mutations that characterize the lambda lineage are in particular, has been considered to have the highest number of deaths per capita in the world. Our assessment shows that the lambda variant has become predominant at the country level during the second wave, despite the parallel circulation of two other variants of concern: alpha and gamma, which have not been let to gain preponderance. We consider that this variant must have played an important role in producing such a high burden of morbidity and mortality in Peru during this second wave, together with the lack of regard to standard prevention measures of our population during the Christmas holidays. Due to the epidemiologic increases we have seen through this year, we believe it could have phenotypic characteristics that can even provide advantages in comparison to these other variants of concern, in particular to the alpha variant. Currently, it is extending throughout South America and is acquiring predominance in Chile and Argentina according to GISAID. 5 This variant has recently been labeled as a VOI by the World Health Organization, 10 as further data is needed to consider it a variant of concern. The lambda variant was detected in more than 70% of analyzed The assumption of the increased transmissibility is aligned to some mutations seen in this variant. The lambda lineage contains a seven-amino-acid deletion in the S gene, which is probably a regression as this deletion is present in predecessor coronaviruses that infect other animal hosts. 12 Noteworthy, the L452Q mutation uniquely present in this variant is very similar to the L452R present in the delta variant and in the epsilon variants, which together with the D614G mutation, are considered to increase the transmissibility. 13, 14 And most importantly, it has the T859N mutation in lambda, also present in variant B.1.526.1 (New York), which has been associated with a reduced neutralization by monoclonal antibodies, and by convalescent and postvaccination sera. 15 The biological significance of other mutations present in the lambda lineage is unknown, so our next step will be to perform studies devoted to assess neutralization of sera from patients with previous infections and vaccinated, as well as observational studies of the clinical profile of these patients including epidemiological studies, to measure transmissibility and impact on re-infections to complete the characterization of this variant, which, in face of the results of these studies, could be upgraded to VOC. Being Peru a country with very high transmission, and having reported the first case of this lambda variant, it is highly likely that it emerged here. Unfortunately, the circumstances that allowed its emergence have not varied greatly, and the vaccination coverage is currently less than 10%, highlighting the possibility of the emergence of new variants. Urgent action is needed to prevent this, focused on greater and quicker access to vaccines to prevent a new wave bringing a new variant. Near-complete genome sequence of a 2019 novel Coronavirus (SARS-CoV-2) strain causing a COVID-19 case in Peru Genomic analysis reveals local transmission of SARS-CoV-2 in early pandemic phase in Peru Nearcomplete genome sequence of a SARS-CoV-2 VOC 202012/01 strain in Peru GISAID: global initiative on sharing all influenza data-from vision to reality 37: novel lineage expanding in Peru and Chile, with a convergent deletion in the ORF1a gene (Δ3675-3677) and a novel deletion in the Spike gene (Δ246-252, G75V, T76I, L452Q, F490S, T859N) Illumina COVIDSeq RUO Kits Reference guide BEAST: Bayesian evolutionary analysis by sampling trees MAFFT multiple sequence alignment software version 7: improvements in performance and usability World Health Organization Tracking SARS-CoV-2 variants Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus Evolutionary relationships and sequence-structure determinants in human SARS coronavirus-2 spike proteins for host receptor recognition The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization 1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies The authors wish to thank the COVID diagnostic team of the National Institute of Health of Peru for their hard contribution in https://orcid.org/0000-0003-0986-0798Henri Bailon https://orcid.org/0000-0002-9593-6092Priscila Lope-Pari https://orcid.org/0000-0002-7439-4351